Indication: Hematological Malignancies
A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)
Lymphoma
Sub-indication: Diffuse Large B-Cell Lymphoma
Line of Therapy: 2nd or 3rd Line
Drug Study
Principal Investigator: Don Stevens, M.D.Norton Cancer Institute
Sponsor: Karyopharm Therapeutics Inc.
Email for more information: Heme-NCIResearch@nortonhealthcare.org
